N4 Pharma (STU:0GO) ROCE % : -104.53% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is N4 Pharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. N4 Pharma's annualized ROCE % for the quarter that ended in Dec. 2023 was -104.53%.

N4 Pharma ROCE % Historical Data

The historical data trend for N4 Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

N4 Pharma ROCE % Chart

N4 Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-104.20

-66.41

-66.28

-55.93

-81.88

N4 Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-72.84	-84.74	-50.88	-73.64	-104.53

N4 Pharma ROCE % Calculation

N4 Pharma's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-1.55	/	( ( (2.491 - 0.09)	+	(1.48 - 0.095) )	/ 2 )
	=	-1.55	/	( (2.401	+	1.385)	/ 2 )
	=	-1.55	/	1.893
	=	-81.88 %

N4 Pharma's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-1.604	/	( ( (1.747 - 0.063)	+	(1.48 - 0.095) )	/ 2 )
	=	-1.604	/	( ( 1.684	+	1.385 )	/ 2 )
	=	-1.604	/	1.5345
	=	-104.53 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

N4 Pharma (STU:0GO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

N4 Pharma ROCE % Related Terms

Thank you for viewing the detailed overview of N4 Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

N4 Pharma (STU:0GO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » N4 Pharma PLC (STU:0GO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N4P.GB:UK N4P:UK

Address

60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR

Website

https://www.n4pharma.com

N4 Pharma PLC is the holding company for N4 UK. N4 UK is a specialist pharmaceutical company engaged in the development of nanoparticle silica delivery systems to improve the cellular delivery and potency of cancer treatments and vaccines. The company operated in one business segment, that of the development and commercialisation of medicines via its delivery system called Nuvec.

N4 Pharma (STU:0GO) Headlines

No Headlines